In this case exploration, a teen survives a gun injury yet denies self-harm, pushing clinicians to read beyond words and plan safety when suicide intent is unclear.
|Articles|January 22, 2007
- Psychiatric Times Vol 24 No 1
- Volume 24
- Issue 1
Psychiatric Times Archives 2002
Psychiatric Times Archives 2002
Advertisement
December 2002
November 2002
October 2002
September 2002
August 2002
July 2002
June 2002
May 2002
April 2002
March 2002
February 2002
January 2002
Articles in this issue
over 19 years ago
Antidepressants' Effects on Driving Abilityover 19 years ago
Green and Dyingover 19 years ago
Drugs for Kids: It's Time to Stop Medicating and Start Practicingover 19 years ago
Self-medication Prevalent in Patients With Anxiety Disordersover 19 years ago
Poetry of the Timesover 19 years ago
Congress Reduces Medicare Payment Cutover 19 years ago
Humorous Movies' Effects in Schizophreniaover 19 years ago
The Link Between Psychotic Disorders and Substance Useover 19 years ago
Intermittent Explosive Disorder: Common but Underappreciatedover 19 years ago
Accepting AcceptanceAdvertisement
Related to this article
How tuning body signals with closed-loop sound and chill tech may ease dissociation and anhedonia, offering drug-free add-ons to therapy.
Two grief experts expose the hidden health, social, and economic toll of bereavement—and the policy gaps leaving millions of grieving Americans unsupported.
Learn how the inhibition constant and 5-HT2A binding explain LSD effects—and why potent atypical antipsychotics may rapidly end a bad trip.
FDA hearing spotlights debates over psychedelic therapy: who administers, how to prove efficacy, and how to track safety as approvals near.
New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.
New research maps an mPFC–zona incerta circuit that drives punishment-resistant binge eating and hints at personalized brain stimulation targets for better treatment.
Phase 3 BLOOM tests 48-hour at-home oral brexanolone for rapid postpartum depression relief, with tighter monitoring after prior trial issues.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Vol 43, Issue 9 - Interactive
2
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
3
Debunking the Top 10 Misleading Claims About Antidepressants
4
What Low Doses of VRAYLAR® (Cariprazine) May Mean for Clinical Practice
5